UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $452.05 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• UBS Asset Management increased its stake in IDEXX Laboratories by 37.0%, now owning 1,076,429 shares valued at approximately $452 million.
• Insider transactions revealed significant selling, with EVP Nimrata Hunt and EVP Sharon E. Underberg reducing their ownership by 28.40% and 46.96% respectively.
• IDEXX reported a quarterly EPS of $3.63, surpassing analyst predictions and projecting a FY 2025 EPS guidance between $12.400 and $12.760.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 37.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,076,429 shares of the company's stock after purchasing an additional 290,551 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 1.34% of IDEXX Laboratories worth $452,046,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MorganRosel Wealth Management LLC acquired a new position in IDEXX Laboratories during the first quarter valued at approximately $26,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after buying an additional 30 shares in the last quarter. WPG Advisers LLC acquired a new position in IDEXX Laboratories during the first quarter valued at approximately $37,000. Bank of Jackson Hole Trust lifted its position in shares of IDEXX Laboratories by 328.6% during the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock worth $39,000 after purchasing an additional 69 shares in the last quarter. Finally, Cornerstone Planning Group LLC lifted its position in shares of IDEXX Laboratories by 108.0% during the first quarter. Cornerstone Planning Group LLC now owns 104 shares of the company's stock worth $44,000 after purchasing an additional 54 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 0.6%

NASDAQ IDXX traded down $4.02 on Friday, reaching $641.14. The stock had a trading volume of 317,919 shares, compared to its average volume of 372,779. The business has a 50 day moving average price of $603.59 and a 200 day moving average price of $513.29. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12. The company has a market capitalization of $51.29 billion, a price-to-earnings ratio of 53.38, a P/E/G ratio of 4.18 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Wall Street Zen raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price on the stock. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research report on Friday, August 15th. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research report on Monday, August 4th. Finally, BTIG Research boosted their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Sharon E. Underberg sold 5,450 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the sale, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. This represents a 46.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the transaction, the director owned 262 shares in the company, valued at $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock worth $34,293,468 over the last 90 days. Company insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.